Healthcare Sales & Marketing Network News: Novartis Pharma

Searching News Database: Novartis Pharma

HSMN NewsFeed - 18 Jun 2025
Neurvati Neurosciences and GRIN Therapeutics Announce Appointment of Gail Farfel, PhD to Their Boards of Directors
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 24 Nov 2023
Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune(R) Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
Biopharmaceuticals Product Recall

HSMN NewsFeed - 31 Oct 2023
FDA Approves Novartis Cosentyx(R) as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Jun 2023
SonoThera(TM) Expands Leadership Team Appointing Carolyne Zimmermann as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Jan 2023
Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Nov 2022
Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jun 2022
INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Apr 2022
FDA approves Novartis Vijoice(R) (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Mar 2022
Orna Therapeutics Bolsters Leadership Team with Key Executive and Board Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Oct 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Sep 2021
Mirati Therapeutics Appoints David Meek as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Jun 2021
Valeo Pharma Announces Commercial Launch of Enerzair(R) Breezhaler(R) and Atectura(R) Breezhaler(R)
Biopharmaceuticals Product Launch

HSMN NewsFeed - 1 Dec 2020
Novartis announces FDA approval of Xolair(R) (omalizumab) for adults with nasal polyps
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Oct 2020
Dewpoint Therapeutics Appoints Ameet Nathwani as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA

HSMN NewsFeed - 31 Mar 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Feb 2020
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Jul 2019
Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 3 Jun 2019
Castle Creek Pharmaceuticals Appoints Mary Spellman, M.D., as Chief Medical Officer and Senior Vice President of Research & Development
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 25 Apr 2019
DURECT Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 21 Feb 2019
Denovo Biopharma Announces New Hires for Positions of Chief Medical Officer of Hematology and Senior Vice President, Regulatory Affairs and Quality Assurance
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Jan 2019
Altavant Sciences Appoints Lyn Baranowski Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Jul 2018
Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance
Biopharmaceuticals Product Recall

HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA

HSMN NewsFeed - 18 May 2018
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
Biopharmaceuticals Devices Drug Delivery FDA

HSMN NewsFeed - 10 May 2018
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 25 Apr 2018
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
Biopharmaceuticals Ophthalmology Product Launch

HSMN NewsFeed - 19 Mar 2018
PMV Pharma Appoints Salim Yazji, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 Mar 2018
Ionis and Akcea Partner to Commercialize Inotersen for hATTR
Biopharmaceuticals Licensing

HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jan 2018
Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Biopharmaceuticals Dermatology

HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Dec 2017
Novartis' combination therapy Tafinlar(R) + Mekinist(R) granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 11 Jul 2017
Evelo Biosciences Announces $50 Million Series B Financing and Expansion of Board and Leadership Team
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Apr 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Apr 2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Mar 2017
George Bickerstaff Elected to Inovio’s Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Feb 2017
Sangamo Therapeutics Announces Chief Financial Officer Succession
Biopharmaceuticals Regenerative Medicine Personnel

HSMN NewsFeed - 17 Feb 2017
AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Sep 2016
BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration
Biopharmaceuticals Licensing

HSMN NewsFeed - 5 May 2016
Aclaris Therapeutics, Inc. Appoints Kevin Scott as Vice President of Sales
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 5 May 2016
Bicycle Therapeutics Strengthens Product Development Capabilities with Key Leadership Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Apr 2016
Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Nov 2015
Seres Therapeutics Appoints Kurt Graves to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Oct 2015
Abbott Announces Positive Clinical Results of Absorb(TM), the Naturally Dissolving Heart Stent
Devices Interventional Cardiology

HSMN NewsFeed - 24 Aug 2015
Chiasma Appoints William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs
Biopharmaceuticals Endocrinology Personnel

HSMN NewsFeed - 24 Jul 2015
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Jul 2015
Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 May 2015
Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 27 Apr 2015
Akorn Announces Recent Executive Appointments
Biopharmaceuticals Generic Personnel

HSMN NewsFeed - 17 Dec 2014
Bovie Medical Corporation Further Expands Its Direct Sales Force
Devices Personnel

HSMN NewsFeed - 16 Dec 2014
Novartis gains FDA approval for Signifor(R) LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Oct 2014
Otonomy Appoints Anthony J. Yost Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Aug 2014
Alzheon Appoints Renowned Industry Leader, Jean-Pierre Sommadossi, PhD, to Board of Directors
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 8 May 2014
Charleston Laboratories, Inc., Bolsters Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 May 2014
Timothy Maloney appointed President of Novartis Pharmaceuticals Canada Inc.
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Apr 2014
Kite Pharma Expands Company's Board of Directors with the Appointment of Jonathan M. Peacock
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Apr 2014
Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 27 Mar 2014
Baxter Announces Plans to Create Two Separate Leading Global Healthcare Companies
Biopharmaceuticals Devices Personnel

HSMN NewsFeed - 19 Feb 2014
Ignyta Appoints Sara Zaknoen, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 24 Oct 2013
Mallinckrodt Pharmaceuticals Announces Executive Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Oct 2013
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Oct 2013
Sideris Pharmaceuticals Completes $32 Million Equity Financing and Signs Agreement With Global Pharmaceutical Company
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 11 Oct 2013
Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Oct 2013
FDA Files Genentech’s Supplemental Biologics License Application of Xolair(R) (omalizumab) for Chronic Idiopathic Urticaria (CIU)
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 8 Oct 2013
MolecularHealth Continues to Grow Management Team with New Chief Commercial Officer
Diagnostics Personalized Medicine Oncology Personnel

HSMN NewsFeed - 21 Aug 2013
Ironwood Pharmaceuticals Appoints Dr. Michael Hall as Senior Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Aug 2013
Enteris BioPharma Appoints Timothy J. Saxon, Vice President of Business Development, to Expand "Peptelligence(TM) Partnering" Program
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 10 Jul 2013
Abbott Announces Approval of Next-Generation XIENCE Xpedition(TM) Drug Eluting Stent System in Japan
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 11 Jun 2013
Questcor Pharmaceuticals Acquires Rights to Synacthen(R)
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 21 May 2013
Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA

HSMN NewsFeed - 29 Apr 2013
Teva Expands Management Team with Appointment of Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jan 2013
Abbott Initiates Clinical Trial of Absorb(TM) in the United States
Devices Interventional Cardiology

HSMN NewsFeed - 18 Dec 2012
Blend Therapeutics Appoints Mark Iwicki as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Nov 2012
Validus Pharmaceuticals Now Exclusively Marketing Six Established U.S. Product Lines Purchased From Leading Healthcare Company
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 1 Oct 2012
XDx Appoints Peter Maag as President and CEO
Diagnostics Personnel

HSMN NewsFeed - 25 Sep 2012
Abbott Announces International Launch of the Absorb(TM) Bioresorbable Vascular Scaffold
Devices Interventional Cardiology

HSMN NewsFeed - 24 Sep 2012
QLT Announces Sale of Visudyne(R) to Valeant Pharmaceuticals
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 4 Sep 2012
Higher dose of Novartis drug Exelon(R) Patch approved by FDA for patients with mild to moderate Alzheimer's disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 20 Aug 2012
Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 31 Jul 2012
Idenix Pharmaceuticals Announces Restructuring of Development and Commercialization Collaboration With Novartis Pharma AG
Biopharmaceuticals

HSMN NewsFeed - 26 Jul 2012
Endocyte Appoints David Meek to Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personalized Medicine Personnel

HSMN NewsFeed - 5 Jun 2012
Kinex Pharmaceuticals Appoints Dr. Jean-Pierre Sommadossi to the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 May 2012
Elixir Medical Announces Excellent Results from DESolve I First-In-Man Study for the Fully Bioresorbable Drug Eluting Coronary Scaffold System
Devices Interventional Cardiology

HSMN NewsFeed - 15 May 2012
Abbott's XIENCE PRIME(TM) and XIENCE V(R) Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 3 May 2012
Creabilis Appoints Dr Simon Russell as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Apr 2012
Insmed Announces First Patient Dosed in Pivotal European Phase 3 Clinical Study of ARIKACE(R) in Cystic Fibrosis Patients with Pseudomonas Lung Infections
Biopharmaceuticals

HSMN NewsFeed - 9 Apr 2012
Abbott Receives Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in Japan
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 3 Feb 2012
Prometheus Announces New Chief Commercial Officer
Diagnostics Personnel

HSMN NewsFeed - 1 Feb 2012
FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Dec 2011
Abbott Initiates Clinical Trial to Study Drug Eluting Bioresorbable Therapy for Treatment of Peripheral Artery Disease
Devices Interventional

HSMN NewsFeed - 8 Dec 2011
Abbott Initiates Clinical Trial to Evaluate the Absorb(TM) Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 21 Nov 2011
Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot(R)
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 1 Nov 2011
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
Devices Interventional Cardiology FDA

HSMN NewsFeed - 15 Sep 2011
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Sep 2011
Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia
Devices

HSMN NewsFeed - 1 Aug 2011
Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Jul 2011
HealOr Names Dr. Michael L. Sabolinski, M.D. as New CEO
Biopharmaceuticals Wound Care Personnel

HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 May 2011
Elixir Medical Receives CE Mark for DESyne(TM) Novolimus Eluting Coronary Stent System
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 12 Apr 2011
Portola Pharmaceuticals Appoints Dr. James Topper to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Apr 2011
Blueprint Medicines Secures $40 Million Series A Financing to Translate New Molecular Data into Personalized Cancer Treatments
Personalized Medicine Oncology Venture Capital

HSMN NewsFeed - 11 Apr 2011
Novartis Therapy Gilenya Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease Severity, New Analysis Shows
Biopharmaceuticals Neurology

HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Feb 2011
Aqua Pharmaceuticals Welcomes Ted White as Vice President, Sales
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Jan 2011
Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 17 Dec 2010
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Dec 2010
Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee
Biopharmaceuticals Devices Personnel

HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Nov 2010
Bausch & Lomb Names Charl van Zyl as Commercial Leader, Europe, Middle East and Africa
Devices Ophthalmology Personnel

HSMN NewsFeed - 23 Nov 2010
FDA Approves Movement Disorder Drug from CNS Therapeutics: Gablofen(R) (Baclofen Injection) for the Treatment of Severe Spasticity
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Nov 2010
Unigene Names Alex Martin VP Business Development and Head of Commercial Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 15 Oct 2010
Watson's Generic Version of Lotrel(R) Receives FDA Approval
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 11 Oct 2010
Phase III Novartis Data Show Potential Benefit of Afinitor(R) Plus Sandostatin(R) LAR Depot in Patients with Advanced Carcinoid Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Devices Interventional Cardiology

HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Outstanding Two-Year Clinical Results Versus TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology

HSMN NewsFeed - 23 Sep 2010
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Sep 2010
Abbott's Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
Devices Interventional Cardiology

HSMN NewsFeed - 22 Sep 2010
Novartis gains FDA approval for Gilenya, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 22 Sep 2010
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Biopharmaceuticals

HSMN NewsFeed - 17 Sep 2010
Elixir Medical Corporation Initiates Enrollment in the EXCELLA BD Randomized Clinical Trial of the Elixir Novolimus Eluting Coronary Stent System with Bioabsorbable Polymer
Devices Interventional Cardiology

HSMN NewsFeed - 8 Sep 2010
XDx Appoints New Vice President of Corporate Development and Legal Affairs
Diagnostics Personnel

HSMN NewsFeed - 27 Aug 2010
Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 23 Jul 2010
Emisphere Provides an Update on Osteoarthritis Phase III Study With Oral Calcitonin
Biopharmaceuticals

HSMN NewsFeed - 15 Jul 2010
Amgen Appoints Jonathan M. Peacock Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 May 2010
Abbott's Groundbreaking Bioresorbable Technology Continues to Demonstrate Exceptional Clinical Results
Devices Interventional Cardiology

HSMN NewsFeed - 6 May 2010
The New England Journal of Medicine Publication of SPIRIT IV Trial Results Confirm Superior Safety and Efficacy of Abbott's XIENCE V(R) Drug Eluting Stent Compared to TAXUS
Devices Interventional Cardiology

HSMN NewsFeed - 22 Apr 2010
Novartis Receives US FDA Approval for Zortress(R) (everolimus) to Prevent Organ Rejection in Adult Kidney Transplant Recipients
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Feb 2010
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Feb 2010
FDA Acknowledges Need for Daily Multiple Sclerosis Pill by Granting Fingolimod Priority Review Status
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Feb 2010
Lantheus Medical Imaging, Inc. Announces Appointment of Robert A. Spurr as Vice President, Sales and Marketing
Biopharmaceuticals Radiology Personnel

HSMN NewsFeed - 8 Feb 2010
Lupin Receives FDA Approval for Amlodipine/Benazepril Capsules
Biopharmaceuticals FDA Generics

HSMN NewsFeed - 18 Jan 2010
T-Ray Science, Inc. Announces Changes in Management
Devices Oncology Personnel

HSMN NewsFeed - 11 Jan 2010
Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications
Biopharmaceuticals

HSMN NewsFeed - 8 Jan 2010
Acetylon Pharmaceuticals Tops Up Series A Financing with $2 Million Note And Appoints Simon Jones VP Biology and Preclinical Development and John van Duzer VP Chemistry and Manufacturing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 4 Jan 2010
Noven Announces New Executive Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Dec 2009
6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Oct 2009
QLT restructures Visudyne(R) agreement
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 13 Oct 2009
Transdel Pharmaceuticals Appoints Dr. Joachim P.H. Schupp as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Oct 2009
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
Biopharmaceuticals Licensing

HSMN NewsFeed - 23 Sep 2009
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology

HSMN NewsFeed - 14 Sep 2009
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 31 Aug 2009
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Devices Interventional Cardiology

HSMN NewsFeed - 24 Aug 2009
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 19 Aug 2009
Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Biopharmaceuticals Onology

HSMN NewsFeed - 13 Aug 2009
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Devices Interventional Cardiology

HSMN NewsFeed - 21 Jul 2009
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Jun 2009
Paulo F. Costa Joins MacroGenics Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Jun 2009
Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 16 Jun 2009
Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
Devices Interventional Cardiology

HSMN NewsFeed - 15 Jun 2009
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 1 Jun 2009
FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
Biopharmaceuticals FDA

HSMN NewsFeed - 21 May 2009
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
Devices Interventional Cardiology

HSMN NewsFeed - 14 May 2009
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval to Proceed With Phase 3 Development of Onalta(TM)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Apr 2009
Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
Devices Interventional

HSMN NewsFeed - 24 Mar 2009
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Devices Interventional Cardiology

HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Mar 2009
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 10 Mar 2009
Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter
Devices Interventional Cardiology

HSMN NewsFeed - 28 Jan 2009
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
Biopharmaceuticals

HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 15 Jan 2009
Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Jan 2009
Valeant Pharmaceuticals Appoints Chief Operating Officer of Specialty Pharmaceuticals
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 17 Dec 2008
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
Devices Interventional Cardiology

HSMN NewsFeed - 2 Dec 2008
Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Biopharmaceuticals Generics Oncology

HSMN NewsFeed - 13 Oct 2008
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Devices Interventional Cardiology

HSMN NewsFeed - 13 Oct 2008
New Data Shows Abbott's Bioabsorbable Drug Eluting Stent is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels
Devices Interventional Cardiology

HSMN NewsFeed - 10 Oct 2008
Elixir Medical Corporation Licenses Myolimus(TM) From Novartis Pharma AG for Site-Specific Drug Delivery Applications
Devices Drug Delivery Licensing Interventional Cardiology

HSMN NewsFeed - 22 Sep 2008
Molecular Insight Pharmaceuticals, Inc. Adds Four Healthcare Industry Experts to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Aug 2008
SciClone Pharmaceuticals Appoints Jeffery Lange as Vice President, Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Jul 2008
Isis Announces Appointment of Martin P. Bedigian, M.D. as Vice President and Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jul 2008
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
Biopharmaceuticals

HSMN NewsFeed - 3 Jul 2008
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology FDA

HSMN NewsFeed - 30 Jun 2008
Noven Names Anthony Venditti Vice President - Marketing & Sales
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Jun 2008
FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Jun 2008
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
Biopharmaceuticals

HSMN NewsFeed - 20 May 2008
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 May 2008
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 May 2008
MacroGenics Appoints New Chief Commercial Officer and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 May 2008
XenoPort Appoints Vincent J. Angotti as Chief Commercialization Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 May 2008
Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial Operations into Canada
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 17 Apr 2008
Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Apr 2008
PDI Signs Promotion Agreement with Major Pharmaceutical Company
Biopharmaceuticals

HSMN NewsFeed - 1 Apr 2008
SPP100 (Tekturna/Rasilez) Reduces Left Ventricular Hypertrophy
Biopharmaceuticals Cardiology

HSMN NewsFeed - 31 Mar 2008
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
Biopharmaceuticals Cardiology

HSMN NewsFeed - 10 Mar 2008
Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Feb 2008
ImmunoCellular Therapeutics Announces New President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Feb 2008
Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jan 2008
Dr. Reddy's Announces Settlement of Exelon(R) (rivastigmine tartrate) ANDA Litigation With Novartis
Biopharmaceuticals Generics Neurology Litigation

HSMN NewsFeed - 21 Jan 2008
US Approval for SPP100 Combined with Diuretic to Treat Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Jan 2008
Breckenridge Pharmaceutical Settles 'Paragraph IV' Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 8 Jan 2008
Callisto Pharmaceuticals Announces Investor Conference Call to Provide Details on Guanilib Strategic Initiative in GI Disorders
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 4 Jan 2008
Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Jan 2008
Noven Announces Changes to Board of Directors and Senior Management
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Dec 2007
Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 20 Dec 2007
Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Dec 2007
Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
Biopharmaceuticals

HSMN NewsFeed - 6 Dec 2007
Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 4 Dec 2007
AVAX Technologies Appoints Dr. Francois Martelet as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Dec 2007
FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Dec 2007
APT Pharmaceuticals Adds Paul Sekhri to Board of Directors
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 26 Nov 2007
Achillion Announces Appointment of New Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Nov 2007
Barr Confirms Patent Challenge of Focalin(R) XR
Biopharmaceuticals Generics

HSMN NewsFeed - 18 Oct 2007
Duska Therapeutics Appoints Shepard Goldberg and Steven Dinh as Board Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Oct 2007
EntreMed Appoints Senior Vice President of Research and Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Oct 2007
Callisto Pharmaceuticals Announces Major Strategic Initiative for Guanilib in GI Disorders
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 28 Sep 2007
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
Biopharmaceuticals

HSMN NewsFeed - 18 Sep 2007
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Biopharmaceuticals

HSMN NewsFeed - 17 Sep 2007
Infinity and MedImmune Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Sep 2007
New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
Biopharmaceuticals

HSMN NewsFeed - 11 Sep 2007
NCCN Updates Dermatofibrosarcoma Protuberans Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Aug 2007
SPP100 (Rasilez) Receives EU Approval
Biopharmaceuticals Regulatory

HSMN NewsFeed - 18 Aug 2007
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Aug 2007
FDA Grants Additional Six Months Marketing Exclusivity for the High Blood Pressure Medicine Diovan(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Jul 2007
Medarex Announces Initiation by Licensing Partner of Phase III Clinical Trial for Muckle Wells Syndrome
Biopharmaceuticals

HSMN NewsFeed - 13 Jul 2007
Valopicitabine Development Program Placed on Clinical Hold in the United States
Biopharmaceuticals

HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 29 Jun 2007
Vertex Pharmaceuticals Announces Two Executive Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jun 2007
Critical Therapeutics and Dey, L.P. Complete Definitive Co-Promotion Agreement for Perforomist(TM) Inhalation Solution
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 21 Jun 2007
LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jun 2007
Exforge(R) Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Jun 2007
APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 2 Jun 2007
INNOVIVE Pharmaceuticals Presents Additional Phase I Data on INNO-406 for Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous Leukemia at the American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2007
Talima Therapeutics Secures $19 Million Series B
Biopharmaceuticals Drug Delivery Venture Capital

HSMN NewsFeed - 21 May 2007
Intercept Pharmaceuticals Expands Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 May 2007
Single-Tablet Combination of Tekturna(R) and Diuretic, an Important New Option for People With High Blood Pressure, Accepted for Review in U.S.
Biopharmaceuticals Cardiology

HSMN NewsFeed - 3 May 2007
Mylan Announces Tentative FDA Approval for Letrozole Tablets, USP
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 2 May 2007
Once-yearly Reclast(R) Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
Biopharmaceuticals Orthopaedic

HSMN NewsFeed - 30 Apr 2007
Sebivo(R) (Telbivudine) Approved in European Union as a New Treatment for Chronic Hepatitis B Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Apr 2007
Study Supports Cost-Effectiveness of Medtronic's Spasticity Treatment for Children with Cerebral Palsy
Devices Neurology

HSMN NewsFeed - 17 Apr 2007
Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Apr 2007
Amarin Appoints Paul F. Duffy to New Position of President - U.S. Commercial Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Mar 2007
Novartis Suspends US Marketing and Sales of Zelnorm(R) in Response to Request from FDA
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 26 Mar 2007
Tekturna(R), First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan(R)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 20 Mar 2007
Idenix Pharmaceuticals, Inc. Announces Resignation of Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Mar 2007
Tekturna(R) - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 2 Mar 2007
SEBIVO(R) (Telbivudine) Approved in China as New Treatment Option for Patients with Chronic Hepatitis B
Biopharmacetuicals Regulatory

HSMN NewsFeed - 27 Feb 2007
Initiation of Phase III Program Using Emisphere's eligen(R) Technology for Oral Salmon Calcitonin
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 26 Feb 2007
Lexicon Announces Executive Management Promotions
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Feb 2007
SEBIVO(R) (telbivudine) Recommended for Approval in European Union as a new Treatment for Patients with Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Jan 2007
Molecular Insight Pharmaceuticals, Inc. Acquires Clinical Stage, Targeted Radiotherapeutic Candidate Onalta(TM) (Formerly OctreoTher(TM))
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 8 Jan 2007
Idenix Pharmaceuticals, Inc. Announces Appointment of Douglas Mayers, M.D. as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jan 2007
ProEthic Pharmaceuticals Announces Positive Phase III Clinical Trial Results for Fast-Acting Migraine Product Candidate
Biopharmaceuticals

HSMN NewsFeed - 5 Jan 2007
Bausch & Lomb Announces Changes in Americas Region Commercial Management
Devices Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 4 Jan 2007
INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug Designation for INNO-406 for the Treatment of Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Dec 2006
Savient Pharmaceuticals Announces Launch of Authorized Generic of Oxandrin(R) with Watson Pharmaceuticals
Biopharmaceuticals Generics

HSMN NewsFeed - 22 Dec 2006
Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients with High Blood Pressure
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Dec 2006
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Dec 2006
Savient Pharmaceuticals Announces Appellate Court Decision in Patent Infringement Lawsuit against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 12 Dec 2006
INNOVIVE Pharmaceuticals Presents Data on Oncology Drug Programs in Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia at American Society of Hematology 48th Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Dec 2006
Norman C. Payson, M.D., Elected to Board of Directors of Idenix Pharmaceuticals
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Dec 2006
Endo Pharmaceuticals Appoints Charles Rowland as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Dec 2006
New Evidence Reinforces Efficacy and Tolerability of Galvus(R) as a New Once-Daily Oral Treatment Option for Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 5 Dec 2006
Savient Pharmaceuticals Obtains Temporary Restraining Order in Patent Infringement Lawsuit Against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 4 Dec 2006
Savient Pharmaceuticals Files Patent Infringement Lawsuit Against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 1 Dec 2006
Amgen Names Yuji Orihara President, Amgen KK
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Nov 2006
Celtic Pharma Appoints Two New Senior Executives
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Nov 2006
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP)
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 15 Nov 2006
Ambrilia Announces European Licensing Partnership with TEVA for its Lead Oncology Product, Octreotide
Biopharmaceuticals Licensing

HSMN NewsFeed - 9 Nov 2006
Genentech Announces Agreement to Acquire Tanox for $20 Per Share
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 8 Nov 2006
Stroke Survivors Benefit Significantly from Targeted Spasticity Treatment Using Medtronic Drug Pump, Study Finds
Devices Neurology Drug Delivery

HSMN NewsFeed - 31 Oct 2006
Boston Scientific Appoints Steven L. Zelenkofske Patient Safety Officer and Vice President, Clinical Sciences for Cardiac Rhythm Management Group
Devices Cardiology Personnel

HSMN NewsFeed - 27 Oct 2006
Idenix Announces New 24-Week Data From A Phase IIb Clinical Trial Of Valopicitabine Plus Pegylated Interferon in Treatment Naive Genotype-1 Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 25 Oct 2006
TYZEKA(TM) (telbivudine) Approved by U.S. Food and Drug Administration (FDA) as a New Treatment for Patients with Chronic Hepatitis B
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Oct 2006
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 20 Oct 2006
FDA Approves Prescription Zaditor(R) for Over-The-Counter Relief From Itchy Eyes
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Oct 2006
Enzo Biochem Appoints Gary C. Cupit, Former Novartis Pharmaceutical Executive, President of Enzo Therapeutics Unit
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Oct 2006
Novartis Launches 'GALIANT' Study Comparing the Investigational Drug Galvus(R) and a Leading Class of Oral Anti-Diabetic Medicines
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 5 Oct 2006
Tracy Lawhon, J.D., Joins Cabrellis Pharmaceuticals as Vice President, Regulatory Affairs and Development Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Oct 2006
Genentech Announces Vice President Appointments in Commercial Operations and Manufacturing
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Oct 2006
Regeneron Names Peter Powchik, M.D., Senior Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Sep 2006
TAP Enters Into Co-Promotion Agreement for Famvir(R)
Biopharmaceuticals

HSMN NewsFeed - 28 Sep 2006
New Data for FTY720 -- Aiming to Become the First Orally Effective Multiple Sclerosis Treatment -- Show Sustained Benefits Over Two Years
Biopharmaceuticals Neurology

HSMN NewsFeed - 22 Sep 2006
ZIOPHARM Appoints John Amedio, Ph.D. as Vice President, Manufacturing & Process Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Sep 2006
Telbivudine Approved in Switzerland for Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Sep 2006
Once-Yearly Reclast(R)* Demonstrates Highly Significant Fracture Risk Reductions in the Treatment of Postmenopausal Osteoporosis, New Study Shows
Biopharmaceuticals

HSMN NewsFeed - 14 Sep 2006
Sara Zaknoen, M.D., Joins Cabrellis Pharmaceuticals as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Sep 2006
FibroGen Appoints Melissa L. Grigorieff, Vice President of Marketing
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jul 2006
Exelon(R) Patch, the first transdermal therapy for Alzheimer's disease, may provide a promising new approach to treatment
Biopharmaceuticals Neurology

HSMN NewsFeed - 27 Jun 2006
The U.S. Food and Drug Administration Approves Exelon(R) (rivastigmine tartrate) as the First Medication Indicated to Treat Parkinson's Disease Dementia
Biopharmaceuticals FDA Neurology

HSMN NewsFeed - 23 May 2006
New Data Show Overactive Bladder Therapy Enablex(R) Does Not Impair Memory Function Compared to Frequently Used Alternative
Biopharmaceuticals Urology Neurology

HSMN NewsFeed - 22 May 2006
Study Reveals Zelnorm(R) May Be a Safe and Effective Treatment for Additional Group of IBS Patients With a Mixed Bowel Pattern
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 22 May 2006
ProEthic Pharmaceuticals Initiates Pivotal Phase III Trial for Fast-Acting Migraine Product Candidate
Biopharmaceuticals

HSMN NewsFeed - 19 May 2006
Biovail to Promote Novartis' Lescol(R) Franchise in Canada; Lescol(R) Provides Treatment Option for Patients Who Need a Statin to Reduce Cardiovascular Risk
Biopharmaceuticals

HSMN NewsFeed - 19 May 2006
Diovan(R) (valsartan) the First Blood Pressure Medication in a Large-Scale Clinical Trial to Lower C-Reactive Protein, an Important Marker of Inflammation
Biopharmaceuticals Cardiology

HSMN NewsFeed - 18 May 2006
Conor Medsystems Announces First Patient Treated with Dual-Drug Coronary Stent
Devices Interventional Cardiology

HSMN NewsFeed - 17 May 2006
FDA Advisory Committee Recommends Approval of Exelon(R) (rivastigmine tartrate) in the Treatment of Dementia Associated with Parkinson's Disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 17 May 2006
Novartis Announces Efficacy Data on New Investigational High Blood Pressure Therapies at The American Society of Hypertension Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 15 May 2006
Novo Nordisk Announces New Key Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 May 2006
Conor Medsystems Initiates RAPID Clinical Study for First Pimecrolimus Drug-Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 10 May 2006
Axcan Pharma appoints new Senior Vice President and Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 May 2006
Novo Nordisk Appoints Edward Williams as Vice President of Biopharmaceuticals
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology

Return to NewsFeed

Additional items found! 276

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 276 additional stories matching:
Novartis Pharma
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!